Results: At the end of 48 weeks, in the Pregablin arm, 14(97.3%) completed the therapy without interruption, one stopped due to excessive somnolence. Duloxetine arm -10(66.6%) completed with interruptions, 4(22.2%) withdrew from the trial due to side events, one left the country. 9(62.2%) achieved SVR in pregablin arm and 5(33.3%) with Duloxetine. Conclusions: Pregablin may be considered with IFN and RBV for better adherence and compliance in achieving SVR in treatment of Chronic Hepatitis C. Larger randomized studies are needed to confirm the findings. In this study we extended this treatment approach to on treatment nonresponders (defined as having detectable HCV-RNA after at least 24 weeks of SOC). Methods: So far, 5 pts. HCV-RNA pos. after 24 weeks of SOC (3 male, 2 female, genotype 1:4; genotype 3a:1, 3 with cirrhosis) participated in this protocol; 4 were treatment naïve pts, 1 relapser to two previous therapies (24 and 48 weeks). 20 mg/kg/d SIL was given for 14 days, SOC was continued. HCV-RNA was quantified by TaqMan (Roche Diagnostics, USA) at monthly intervals on standard treatment and weekly after starting SIL. Results: All patients received at least 24 weeks of SOC, at week 24 3 had a log drop < 3, two patients had detectable but unquantifiable HCV-RNA (< 15 IU/mL). After 14 days of SIL all 5 had undetectable HCV-RNA, in one HCV-RNA increased to 100 IU/ml and recived after a second course of SIL. .All 5 patients are still on SOC and are HCV-RNA negative. Conclusion: SIL iv. Is an effective "rescue treatment" for on treatment nonresponders to full dose of peginterferon/ribavirin combination therapy.